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Abstract
Background Topical therapies are the mainstay of treatment for psoriasis vulgaris. The ﬁxed combination of cal-
cipotriol (Cal) 50 lg/g plus betamethasone 0.5 mg/g (as dipropionate; BD) is a ﬁrst-line topical treatment and available
as a gel or ointment. The use of these ﬁxed combination products was compared in PRO-long, a long-term noninterven-
tional study, for which interim results (4 and 12 weeks) have previously been reported.
Objective To describe and compare patients’ perspectives on the ﬁxed combination gel and ointment formulations; to
include efﬁcacy, adherence behaviour, treatment satisfaction and health-related quality of life (HRQoL) aspects during
long-term real-life psoriasis management.
Methods PRO-long was a multicentre, prospective, observational, 52-week study of patients prescribed ﬁxed combi-
nation Cal/BD gel or ointment in clinical practice. For ﬁnal analysis the following were assessed at weeks 24, 36 and 52:
differences in the proportion of patients with ‘mild’/‘very mild’ disease according to patient’s global assessment of dis-
ease severity, adherence behaviour, treatment satisfaction (nine-item treatment satisfaction questionnaire for medica-
tion) and HRQoL (Skindex-29).
Results Patients (n = 328) were prescribed once-daily Cal/BD gel (n = 152) or ointment (n = 176). At week 52, a higher
proportion of patients reported that the severity of their psoriasis was ‘mild’/‘very mild’ vs. baseline (gel: 60.2 vs. 47.1%;
ointment: 58.8 vs. 42.4%), with greater treatment satisfaction reported in patients using gel vs. those using ointment. A
higher proportion of patients found the gel ‘easy’ to use compared with the ointment (66.7 vs. 45.2%). Daily application
of treatment took ≤5 min for 86.1% of patients using gel and 71.0% of patients using ointment.
Conclusion This real-life study has demonstrated similar effectiveness between the Cal/BD formulations. However,
over a 52-week treatment period, patients reported greater treatment satisfaction with the gel, which was considered
easier to use, faster to apply and overall a more convenient product.
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Introduction
Psoriasis is a chronic skin disorder with inflammatory involve-
ment1 with a global incidence of 1–3%.1–3 Psoriasis vulgaris, the
most common form of psoriasis, manifests in sharply demar-
cated, scaly plaques, usually present on the scalp, limbs and
trunk.4 These plaques are the result of epidermal hyperplasia
with abnormal keratinocyte differentiation; infiltration of
inflammatory cells into the epidermis and dermis; and increased
dermal vascularity.5,6 Psoriasis is associated with a number of
comorbidities and psychological disorders,4 and impacts the
Previous presentations and publications: Poster presentation of interim analysis
at EADV 2013; Poster presentation of ﬁnal analysis at EADV 2014; Interim
analysis original article in JEADV 2014.19
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patient’s ability to perform daily activities and form social rela-
tionships.7 Psoriasis has been reported to reduce patient health-
related quality of life (HRQoL) to an extent comparable with
diseases, such as depression and cancer.8
Treatment nonadherence is a universal medical issue, particu-
larly in chronic disorders. For patients prescribed topical treat-
ment, nonadherence is further exacerbated by the requirement
of application, which can be time-consuming and cumbersome.
This is a challenge in psoriasis as topicals are the mainstay of
treatment for mild-to-moderate disease.9 A real-life study
showed that 46% of psoriasis patients were not fully adherent to
their prescribed topical therapy, applying treatment only when
they felt it necessary.10 The choice of vehicle is one of the key
factors affecting patient adherence to topical psoriasis treatment.
A number of formulations are available, including creams, gels
and ointments, although some are perceived as less convenient
and more difficult to apply than others;11,12 patients generally
prefer a gel, for example, to an ointment.13,14
Treatment nonadherence impacts the ‘real-life effectiveness’
of a drug (defined as “a function of drug efficacy [determined by
randomized clinical trial results] and patient safety and compli-
ance”).15 Clinical trials provide a stringent environment in
which to determine drug efficacy and tolerability, but do not
accurately reflect real-life conditions16 and evidence of patient
use from daily clinical practice is limited.
Fixed combination calcipotriol (50 lg/g) plus betamethasone
(0.5 mg/g; as dipropionate), available in gel and ointment for-
mulations, is a recommended first-line treatment for mild-to-
moderate psoriasis vulgaris.9,17,18 PRO-long (Patient-Reported
Outcomes in a long-term study) was the first direct ‘real-life’
study to compare patients’ perspectives on the gel to that of the
ointment formulation of this fixed combination, for up to
52 weeks of treatment. From interim analysis (4 and 12 weeks),
patients found the gel more convenient, easier and faster to
apply than the ointment.19
Here, we report the final analysis of this noninterventional
study, including assessments at 24, 36 and 52 weeks after initia-
tion of treatment.
Materials and methods
Full details of the methods have previously been reported with
the interim analysis.19 In brief, psoriasis patients aged ≥18 years
and eligible for topical treatment were prescribed fixed combina-
tion calcipotriol (50 lg/g) plus betamethasone (0.5 mg/g; as
dipropionate) gel or ointment once daily, for up to 52 weeks.
Baseline disease severity was evaluated using the physician’s glo-
bal assessment of disease severity (PGA; 5-point scale: very mild,
mild, moderate, severe, very severe), and extent of body surface
area affected with psoriasis. Assessments conducted for interim
analysis (4 and 12 weeks) were also conducted at weeks 24, 36
and 52. Efficacy was evaluated according to patient’s global
assessment of disease severity (PaGA; same 5-point scale as
PGA). Adherence behaviour was assessed using a study-specific
questionnaire.19 Treatment satisfaction was assessed using the
nine-item treatment satisfaction questionnaire for medication
(TSQM-9),20 consisting of three domains: effectiveness, conve-
nience and overall satisfaction (overall satisfaction questions
were completed at week 52 only). HRQoL was assessed using the
Skindex-29 questionnaire, consisting of three domains: emo-
tions, symptoms and functioning.21
Statistical analysis was performed as for the interim analysis.19
The chi-squared test was used to compare the proportion of
patients with controlled disease between treatments and McNe-
mar’s test was used to confirm the statistical significance of
changes in the proportion of patients with controlled disease
from baseline.19 For patients who had not completed week-52
questionnaires, PaGA was imputed using the last observation
carried forward method. No imputation was applied to the other
parameters assessed; missing data were treated as missing
completely at random and not replaced.
Final analysis endpoints
The primary endpoint was the difference in the proportion of
patients with controlled disease (defined as ‘mild’ or ‘very mild’
according to PaGA) between the gel and ointment at week 52.
Secondary endpoints included patients’ perspectives on adher-
ence behaviour, treatment satisfaction and HRQoL at weeks 24,
36 and 52, compared with baseline, as well as differences in the
proportion of patients with controlled disease between the gel
and the ointment at weeks 24 and 36.
Results
Patients
In total, 328 patients (gel, n = 152; ointment, n = 176) were
included in this study. Patient baseline characteristics across
treatment groups were generally well-balanced (Table 1). In this
52-week, noninterventional study, noncompletion was observed
for a large proportion of patients (73%; Fig. 1); post-hoc analysis
revealed that baseline characteristics were similar for completers
and noncompleters (Table 2).
Efﬁcacy
A significant increase in the proportion of patients with con-
trolled disease (‘mild’ or ‘very mild’ compared with baseline,
according to PaGA) was seen with the gel (increase: 13.1%;
P = 0.009) and the ointment (increase: 16.4%; P = 0.0003) at
week 52 (Fig. 2a,b). This significant increase was also seen at
earlier time points (week 24: 16.0 [gel] and 14.7% [ointment];
P = 0.0009 and P = 0.0007; week 36: 12.3 and 18.1%;
P = 0.0164 and P < 0.0001; Fig. 2c). There were no statistically
significant differences in the proportion of patients with con-
trolled disease between treatment groups at any time point
(Fig. 2c).
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Adherence behaviour
Patient adherence to treatment was assessed using a study-speci-
fic questionnaire.19 At week 52, a large proportion of patients
(gel: 86.1%; ointment: 67.8%) reported that application of
treatment was ‘never’ or ‘rarely’ too great a burden. No patients
using gel reported that the burden of application was ‘often’ or
‘always’ too great compared with 16.1% of patients using oint-
ment (Fig. 3a). Daily application of treatment took 5 min or less
for 86.1% of patients using gel and 71.0% of patients using oint-
ment at 52 weeks (Fig. 3b).
Treatment satisfaction
Treatment satisfaction was assessed using TSQM-9 (comprising
convenience, effectiveness and overall satisfaction [at week 52
only] domains). At week 52, patients found that the gel was sig-
nificantly more convenient (P = 0.033) and effective
(P = 0.003) than the ointment (Fig. 4a). At weeks 24 and 36,
significant differences in convenience between the gel and oint-
ment were also seen (P = 0.027 and P < 0.001, respectively). At
week 52, a greater proportion of patients using the gel compared
with those using ointment found it ‘easy’ to use (66.7 vs.
45.2%), ‘easy’ to plan treatment (61.1 vs. 38.7%), or ‘easy’ to
apply (72.2 vs. 45.2%), although this led to a significant differ-
ence in TSQM-9 mean scores for ease of application only
(P = 0.019; Fig. 4b). Significantly favourable responses to the
gel over ointment were seen in all TSQM-9 components for
effectiveness at week 52 (Fig. 4c) and patient responses to ‘appli-
cation time’ were also significantly more positive for the gel
compared with ointment at weeks 24 and 36 (P = 0.009 and
P = 0.026, respectively). For week-52 overall satisfaction,
patients rated the gel significantly greater at providing benefit
than the ointment (P = 0.031; Fig. 4d) and were in favour of the
gel, although not significantly so, when asked whether the posi-
tives of their treatment outweighed the negatives (P = 0.296).
However, a numerical difference in favour of ointment was
observed when patients evaluated their global satisfaction with
treatment (P = 0.726), although the TSQM-9 mean overall satis-
faction domain score was similar for both treatments
(P = 0.192; Fig. 4a).
HRQoL
According to Skindex-29 assessment of HRQoL, improvements
from baseline in mean scores at week 52 were greater for patients
treated with the gel vs. ointment (Fig. 5), although these differ-
ences did not reach significance.
Discussion
This 52-week, noninterventional study compared patients’ per-
spectives on the use of calcipotriol (50 lg/g) plus betamethasone
(0.5 mg/g; as dipropionate) gel with ointment for the manage-
ment of psoriasis vulgaris. Patients who completed this study
reported greater treatment satisfaction with the gel compared
Table 1 Patient demographics and baseline clinical characteris-
tics (by treatment)
Patients
using
gel (n = 152)
Patients using
ointment
(n = 176)
All patients
(n = 328)
Gender, n (%)
Male 91 (59.9) 98 (55.7) 189 (57.6)
Female 61 (40.1) 78 (44.3) 139 (42.4)
Median age, years (range) 47 (11–77) 42 (17–73) 44 (11–77)
Study site, n (%)
Belgium 2 (1.3) 78 (44.3) 80 (24.4)
Netherlands 119 (78.3) 40 (22.7) 159 (48.5)
Years suffering from psoriasis, n (%)
<1 10 (6.6) 20 (11.4) 30 (9.1)
1–5 39 (25.7) 47 (26.7) 86 (26.2)
6–10 29 (19.1) 33 (18.8) 62 (18.9)
11–15 18 (11.8) 23 (13.1) 41 (12.5)
16–20 15 (9.9) 15 (8.5) 30 (9.1)
>20 41 (27.0) 38 (21.6) 79 (24.1)
Percentage body surface area affected by psoriasis, n (%)
1–5 42 (27.6) 80 (45.5) 122 (37.2)
6–10 46 (30.3) 43 (24.4) 89 (27.1)
11–15 16 (10.5) 23 (13.1) 39 (11.9)
16–20 14 (9.2) 14 (8.0) 28 (8.5)
21–30 24 (15.8) 9 (5.1) 33 (10.1)
31–40 8 (5.3) 4 (2.3) 12 (3.7)
>40 2 (1.3) 2 (1.1) 4 (1.2)
PGA disease severity, n (%)
Very mild 18 (11.8) 24 (13.6) 42 (12.8)
Mild 58 (38.2) 63 (35.8) 121 (36.9)
Moderate 66 (43.4) 75 (42.6) 141 (43.0)
Severe 10 (6.6) 14 (8.0) 24 (7.3)
Very severe – – –
Comorbidity, n (%)
Hypertension 23 (15.1) 30 (17.0) 53 (16.2)
Diabetes 10 (6.6) 8 (4.5) 18 (5.5)
Dyslipidaemia 11 (7.2) 21 (11.9) 32 (9.8)
None of the above 125 (82.2) 135 (76.7) 260 (79.3)
Topicals used during the last year for psoriasis on the body
Fixed combination
calcipotriol plus
betamethasone
dipropionate, n (%)
40 (26.3) 55 (31.3) 95 (29.0)
Vitamin D analogues, n (%) 14 (9.2) 19 (10.8) 33 (10.1)
Steroids, n (%) 60 (39.5) 66 (37.5) 126 (38.4)
Combination of steroids and
vitamin D analogues, n (%)
2 (1.3) 13 (7.4) 15 (4.6)
Other, n (%) 7 (4.6) 10 (5.7) 17 (5.2)
Prescribed systemic treatment at baseline
Methotrexate, n (%) 16 (10.5) 12 (6.8) 28 (8.5)
Cyclosporine, n (%) 1 (0.7) 4 (2.3) 5 (1.5)
Acitretin, n (%) 4 (2.6) 6 (3.4) 10 (3.0)
Fumaric acid, n (%) 12 (7.9) 1 (0.6) 13 (4.0)
Biologicals, n (%) 9 (5.9) 8 (4.5) 17 (5.2)
Other, n (%) 2 (1.3) 1 (0.6) 3 (0.9)
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with ointment: it was considered easier to use, faster to apply
and overall more convenient than the ointment. This supports
the findings of the interim analysis, where a difference in conve-
nience was observed in favour of the gel by the first assessment
(week 4).19
Treatment adherence in chronic diseases remains a challenge
and adherence rates to topical treatments are low, with over a
third of patients not using their medication as prescribed.13 Even
for short-term topical psoriasis treatment (up to 8 weeks) in
clinical trials, patient adherence is still poor, ranging between 51
and 58%.22–24 Furthermore, in a 52-week, randomized study,
the withdrawal rate of patients using the fixed combination gel
was 21.4 and 39.8% of those using calcipotriol gel.25 For PRO-
long, being a 52-week, noninterventional study, high rates of
noncompletion were expected; this was found to be the case,
regardless of the overall preference for the gel; however, post-hoc
analysis indicated that patient demographics and baseline char-
acteristics were generally similar for completers compared to
noncompleters and a sensitivity analysis supported the final
analysis.
Cosmetically elegant products, such as gels and creams, are
generally considered less greasy, taking less time to apply than
ointments.13,26 As such, patients perceive gels and creams to be
more acceptable than ointments for topical treatment.11 PRO-
long supports the difference in application time between topical
preparations, as more patients using the gel (86.1%) compared
with the ointment (71.0%) could apply their treatment within
5 min. Treatment effectiveness is a key aspect of adherence, as
patients are more likely to continue with treatments that they
judge to be beneficial.27 In our study, there were patients using
the ointment who reported good treatment satisfaction and
completed the study. This finding is in agreement with previ-
ously reported incidental evidence that some patients like using
the ointment and do not notice a cosmetic difference between
formulations.26 Furthermore, this finding demonstrates that
resolving treatment adherence is not as simple as developing a
more cosmetically elegant vehicle. Each patient has a different
experience of previous treatments and their own expectations of
the current course of treatment, and involving patients in treat-
ment decisions may increase rates of adherence.26 A recent
expert review of the management of topical psoriasis treatment,
using the fixed combination calcipotriol plus betamethasone
dipropionate gel as a working example, highlighted the impor-
tance of tailoring treatment to the needs of each patient.26 On
the basis of our findings, as well as the recommendations pre-
sented within the recent expert review,26 we suggest that patients
are given a choice between gel and ointment formulations.
A noninterventional study design is important to gain insight
into real-life effectiveness, although this design has its limita-
tions. Patients were prescribed gel or ointment at the dermatolo-
gists’ discretion and therefore bias may have been introduced
during the selection process. This bias may have been augmented
Prescribed treatment
(n = 328)
Cal/BD gel
(n = 152)
Treatment use at Week 4 (n = 82)
• Gel only, n = 44
• Gel plus other treatment, n = 32
• Not necessary as clear/minimal disease, n = 0
Treatment use at Week 4 (n = 74)
• Ointment only, n = 32
• Ointment plus other treatment, n = 36
• Not necessary as clear/minimal disease, n = 1
Treatment use at Week 12 (n = 76)
• Gel only, n = 38
• Gel plus other treatment, n = 30
• Not necessary as clear/minimal disease, n = 2
Treatment use at Week 12 (n = 62)
• Ointment only, n = 27
• Ointment plus other treatment, n = 26
• Not necessary as clear/minimal disease, n = 6
Treatment use at Week 24 (n = 61)
• Gel only, n = 28
• Gel plus other treatment, n = 20
• Not necessary as clear/minimal disease, n = 4
Treatment use at Week 24 (n = 54)
• Ointment only, n = 29
• Ointment plus other treatment, n = 13
• Not necessary as clear/minimal disease, n = 7
Treatment use at Week 36 (n = 49)
• Gel only, n = 24
• Gel plus other treatment, n = 16
• Not necessary as clear/minimal disease, n = 3
Treatment use at Week 36 (n = 49)
• Ointment only, n = 24
• Ointment plus other treatment, n = 15
• Not necessary as clear/minimal disease, n = 4
Treatment use at Week 52 (n = 45)
• Gel only, n = 21
• Gel plus other treatment, n = 15
• Not necessary as clear/minimal disease, n = 3
Treatment use at Week 52 (n = 42)
• Ointment only, n = 20
• Ointment plus other treatment, n = 11
• Not necessary as clear/minimal disease, n = 3
Cal/BD ointment
(n = 176)
ENROLMENT
FOLLOW-UP
Figure 1 Patient disposition.
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by the limited availability of the gel formulation in Belgium.
Furthermore, incomplete follow-up is common in noninterven-
tional studies and limits the power of these studies for
Table 2 Patient demographics and baseline clinical characteris-
tics (completers vs. noncompleters)
Completers
(n = 87)
Noncompleters
(n = 241)
Gender, n (%)
Male 53 (60.9) 136 (56.4)
Female 34 (39.1) 105 (43.6)
Median age, years (range) 52 (11–77) 42 (17–77)
Study site, n (%)
Belgium 32 (36.8) 48 (19.9)
Netherlands 55 (63.2) 104 (43.2)
Years suffering from psoriasis, n (%)
<1 11 (12.6) 19 (7.9)
1–5 19 (21.8) 67 (27.8)
6–10 17 (19.5) 45 (18.7)
11–15 8 (9.2) 33 (13.7)
16–20 6 (6.9) 24 (10.0)
>20 26 (29.9) 53 (22.0)
Percentage body surface area affected by psoriasis, n (%)
1–5 33 (37.9) 89 (36.9)
6–10 26 (29.9) 63 (26.1)
11–15 14 (16.1) 25 (10.4)
16–20 5 (5.7) 23 (9.5)
21–30 7 (8.0) 26 (10.8)
31–40 2 (2.3) 10 (4.1)
>40 – 4 (1.7)
PGA disease severity, n (%)
Very mild 11 (12.6) 31 (12.9)
Mild 40 (46.0) 81 (33.6)
Moderate 34 (39.1) 107 (44.4)
Severe 2 (2.3) 22 (9.1)
Very severe – –
Comorbidity, n (%)
Hypertension 15 (17.2) 38 (15.8)
Diabetes 4 (4.6) 14 (5.8)
Dyslipidaemia 5 (5.7) 27 (11.2)
None of the above 70 (80.5) 190 (78.8)
Topicals used for psoriasis of the body during the year prior to start
of treatment
Fixed combination calcipotriol
plus betamethasone
dipropionate, n (%)
29 (33.3) 66 (27.4)
Vitamin D analogues, n (%) 7 (8.0) 26 (10.8)
Steroids, n (%) 35 (40.2) 91 (37.8)
Combination of steroids
and vitamin D analogues, n (%)
7 (8.0) 8 (3.3)
Other, n (%) 5 (5.7) 12 (5.0)
Prescribed systemic treatment at baseline
Methotrexate, n (%) 5 (5.7) 23 (9.5)
Cyclosporine, n (%) 1 (1.1) 4 (1.7)
Acitretin, n (%) 3 (3.4) 7 (2.9)
Fumaric acid, n (%) 3 (3.4) 10 (4.1)
Biologicals, n (%) 7 (8.0) 10 (4.1)
Other, n (%) – 3 (1.2)
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comparator analysis. However, as previously discussed, post-hoc
analysis showed no difference in baseline characteristics between
completers and noncompleters, and the sample sizes for both
groups were similar at week 52, indicating similar rates of non-
completion for both treatments.
This study has drawn on the perspectives of patients
managing their psoriasis with the use of topical therapy, over
a long treatment period. It provides a valuable insight into the
behaviour of psoriasis patients and their perspectives on the
fixed combination gel and ointment formulations. Patients
found the gel to be more convenient than the ointment, as it
was easier to use, faster to apply and had similar efficacy. Both
formulations are effective in daily clinical practice and deci-
sions on which formulation to prescribe should be made on a
per-patient basis.
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